Literature DB >> 34889407

Whom should we treat with novel agents? Specific indications for specific and challenging populations.

Lindsay Wilde1, Margaret Kasner1.   

Abstract

A relative wealth of new therapies for acute myeloid leukemia (AML) have led to a rapid shift in treatment paradigms for this disease. Understanding whom, when, and how to treat is more complex than ever before. Here we explore whom to treat with these available new therapies, focusing on special patient populations that include older adults, those with relapsed disease, and those with TP53-mutated AML. These high-risk subgroups are some of the most challenging to care for, but novel treatments are providing them with new hope.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34889407      PMCID： PMC8791172          DOI： 10.1182/hematology.2021000228

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  30 in total

1.  Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk
Journal:  N Engl J Med       Date:  2016-06-09       Impact factor: 91.245

Review 2.  Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.

Authors:  Rory M Shallis; Rong Wang; Amy Davidoff; Xiaomei Ma; Amer M Zeidan
Journal:  Blood Rev       Date:  2019-04-29       Impact factor: 8.250

3.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.

Authors:  C P Leith; K J Kopecky; J Godwin; T McConnell; M L Slovak; I M Chen; D R Head; F R Appelbaum; C L Willman
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

4.  Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

Authors:  Lori Muffly; Marcelo C Pasquini; Michael Martens; Ruta Brazauskas; Xiaochun Zhu; Kehinde Adekola; Mahmoud Aljurf; Karen K Ballen; Ashish Bajel; Frederic Baron; Minoo Battiwalla; Amer Beitinjaneh; Jean-Yves Cahn; Mathew Carabasi; Yi-Bin Chen; Saurabh Chhabra; Stefan Ciurea; Edward Copelan; Anita D'Souza; John Edwards; James Foran; Cesar O Freytes; Henry C Fung; Robert Peter Gale; Sergio Giralt; Shahrukh K Hashmi; Gerhard C Hildebrandt; Vincent Ho; Ann Jakubowski; Hillard Lazarus; Marlise R Luskin; Rodrigo Martino; Richard Maziarz; Philip McCarthy; Taiga Nishihori; Rebecca Olin; Richard F Olsson; Attaphol Pawarode; Edward Peres; Andrew R Rezvani; David Rizzieri; Bipin N Savani; Harry C Schouten; Mitchell Sabloff; Matthew Seftel; Sachiko Seo; Mohamed L Sorror; Jeff Szer; Baldeep M Wirk; William A Wood; Andrew Artz
Journal:  Blood       Date:  2017-07-03       Impact factor: 22.113

5.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

6.  Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).

Authors:  Thomas Cluzeau; Marie Sebert; Ramy Rahmé; Stefania Cuzzubbo; Jacqueline Lehmann-Che; Isabelle Madelaine; Pierre Peterlin; Blandine Bève; Habiba Attalah; Fatiha Chermat; Elsa Miekoutima; Odile Beyne Rauzy; Christian Recher; Aspasia Stamatoullas; Lise Willems; Emmanuel Raffoux; Céline Berthon; Bruno Quesnel; Michael Loschi; Antoine F Carpentier; David A Sallman; Rami Komrokji; Anouk Walter-Petrich; Sylvie Chevret; Lionel Ades; Pierre Fenaux
Journal:  J Clin Oncol       Date:  2021-02-18       Impact factor: 44.544

7.  Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.

Authors:  David A Sallman; Amy E DeZern; Guillermo Garcia-Manero; David P Steensma; Gail J Roboz; Mikkael A Sekeres; Thomas Cluzeau; Kendra L Sweet; Amy McLemore; Kathy L McGraw; John Puskas; Ling Zhang; Jiqiang Yao; Qianxing Mo; Lisa Nardelli; Najla H Al Ali; Eric Padron; Greg Korbel; Eyal C Attar; Hagop M Kantarjian; Jeffrey E Lancet; Pierre Fenaux; Alan F List; Rami S Komrokji
Journal:  J Clin Oncol       Date:  2021-01-15       Impact factor: 44.544

8.  Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

Authors:  Abhishek Maiti; Caitlin R Rausch; Jorge E Cortes; Naveen Pemmaraju; Naval G Daver; Farhad Ravandi; Guillermo Garcia-Manero; Gautam Borthakur; Kiran Naqvi; Maro Ohanian; Nicholas J Short; Yesid Alvarado; Tapan M Kadia; Koichi Takahashi; Musa Yilmaz; Nitin Jain; Steven Kornblau; Guillermo Montalban Bravo; Koji Sasaki; Michael Andreeff; Prithiviraj Bose; Alessandra Ferrajoli; Ghayas C Issa; Elias J Jabbour; Lucia Masarova; Philip A Thompson; Sa Wang; Sergej Konoplev; Sherry A Pierce; Jing Ning; Wei Qiao; John S Welch; Hagop M Kantarjian; Courtney D DiNardo; Marina Y Konopleva
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

9.  Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.

Authors:  Victoria V Prassek; Maja Rothenberg-Thurley; Maria C Sauerland; Tobias Herold; Hanna Janke; Bianka Ksienzyk; Nikola P Konstandin; Dennis Goerlich; Utz Krug; Andreas Faldum; Wolfgang E Berdel; Bernhard Wörmann; Jan Braess; Stephanie Schneider; Marion Subklewe; Stefan K Bohlander; Wolfgang Hiddemann; Karsten Spiekermann; Klaus H Metzeler
Journal:  Haematologica       Date:  2018-06-14       Impact factor: 9.941

10.  Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.

Authors:  Tobias Herold; Maja Rothenberg-Thurley; Victoria V Grunwald; Hanna Janke; Dennis Goerlich; Maria C Sauerland; Nikola P Konstandin; Annika Dufour; Stephanie Schneider; Michaela Neusser; Bianka Ksienzyk; Philipp A Greif; Marion Subklewe; Andreas Faldum; Stefan K Bohlander; Jan Braess; Bernhard Wörmann; Utz Krug; Wolfgang E Berdel; Wolfgang Hiddemann; Karsten Spiekermann; Klaus H Metzeler
Journal:  Leukemia       Date:  2020-03-30       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.